Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225260 · ClinicalTrials.gov registry record · Phase 3
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 902
- Enrollment target
NCT04225260 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 902 participants.
The verdict
NCT04225260, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 902 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
Interventions
- BIOLOGICAL botulinum toxin neuromodulator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2021-05-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225260
The ClinicalTrials.gov registry entry for NCT04225260 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which botulinum toxin neuromodulator is the first listed.
NCT04225260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04225260 about?
NCT04225260 is a clinical study titled "Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines". This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
What is the current status of trial NCT04225260?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 902 participants. The study started on 2020-01-27. Estimated completion is 2021-05-21.
What interventions are being tested in trial NCT04225260?
The interventions under investigation include: botulinum toxin neuromodulator (BIOLOGICAL).
Who is sponsoring clinical trial NCT04225260?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.